Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.

TheMotleyFool

0 0

AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.: https://g.foolcdn.com/editorial/images/717305/gettyimages-936284004.jpg

AbbVie (NYSE: ABBV) boasts a portfolio of drugs across immunology, neuroscience, aesthetics, oncology, and eye care. Yet investors' focus lately has been on the fate of one particular product: the immunology drug Humira. That's because it's set to face competition in the U.S. as of this month.

Why is this such a problem? It's because Humira has become a megablockbuster. In 2021, the product brought in more than $20 billion in sales. And over its two decades on the market, Humira has generated almost $200 billion in sales, according to BioPharma Dive.

But I think investors shouldn't worry too much about the upcoming loss of exclusivity. Here's why.

Source Fool.com

Like: 0

ABBV

Share